SUPN (STOCKS)
Supernus Pharmaceuticals, Inc.
$49.950000
-0.730000 (-1.44%)
Prev close: $50.680000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jack A. Khattar
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,875.05M
- Employees
- 674
- P/E (TTM)
- -73.04
- P/B (TTM)
- 2.74
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
6
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$0.84 | $0.35 | +0.4932 | +142.21% |
|
Sep 2025 (Q3)
|
$1.01 | $0.60 | +0.4082 | +67.83% |
|
Jun 2025 (Q2)
|
$0.90 | $0.48 | +0.4206 | +87.73% |
|
Mar 2025 (Q1)
|
$0.44 | $0.38 | +0.0592 | +15.55% |
Financial Statements
| Revenues | $718.95M |
| Benefits Costs and Expenses | $767.98M |
| Cost Of Revenue | $74.56M |
| Costs And Expenses | $781.24M |
| Gross Profit | $644.39M |
| Nonoperating Income/Loss | $13.25M |
| Operating Expenses | $706.67M |
| Selling, General, and Administrative Expenses | $485.56M |
| Depreciation and Amortization | $2.10M |
| Research and Development | $106.24M |
| Other Operating Expenses | $112.78M |
| Operating Income/Loss | -$62.28M |
| Income/Loss From Continuing Operations After Tax | -$38.55M |
| Income/Loss From Continuing Operations Before Tax | -$49.03M |
| Income Tax Expense/Benefit | -$10.48M |
| Income Tax Expense/Benefit, Current | -$15.69M |
| Income Tax Expense/Benefit, Deferred | $5.21M |
| Net Income/Loss | -$38.55M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$38.55M |
| Net Income/Loss Available To Common Stockholders, Basic | -$38.55M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.68 |
| Diluted Earnings Per Share | -$0.68 |
| Basic Average Shares | 56,451,136 |
| Diluted Average Shares | 56,451,136 |
| Assets | $1.45B |
| Current Assets | $644.18M |
| Inventory | $112.48M |
| Other Current Assets | $531.70M |
| Noncurrent Assets | $808.47M |
| Fixed Assets | $10.53M |
| Intangible Assets | $569.46M |
| Other Non-current Assets | $228.48M |
| Liabilities | $390.93M |
| Current Liabilities | $338.17M |
| Accounts Payable | $2.68M |
| Wages | $29.45M |
| Other Current Liabilities | $306.05M |
| Noncurrent Liabilities | $52.76M |
| Equity | $1.06B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.06B |
| Liabilities And Equity | $1.45B |
| Net Cash Flow From Operating Activities | $47.33M |
| Net Cash Flow From Operating Activities, Continuing | $47.33M |
| Net Cash Flow From Investing Activities | $4.11M |
| Net Cash Flow From Investing Activities, Continuing | $4.11M |
| Net Cash Flow From Financing Activities | $9.13M |
| Net Cash Flow From Financing Activities, Continuing | $9.13M |
| Net Cash Flow | $60.57M |
| Net Cash Flow, Continuing | $60.57M |
| Comprehensive Income/Loss | -$38.41M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$38.41M |
| Other Comprehensive Income/Loss | -$38.41M |
| Other Comprehensive Income/Loss Attributable To Parent | $145.00K |